Department of Gastroenterology, Yamagata University Faculty of Medicine, Yamagata, Japan.
CREST, Yamagata, Japan.
Adv Exp Med Biol. 2018;1103:243-253. doi: 10.1007/978-4-431-56847-6_13.
Liver diseases account for one of the leading causes of deaths in global health care. Furthermore, chronic liver failure such as liver cirrhosis is, namely, responsible for these fatal conditions. However, only liver transplantation is an established treatment for this end-stage condition, although the availability of this salvage treatment option is quite limited. Thus, the novel therapy such as artificial liver devices or cellular administration has been regarded as feasible. Especially cellular therapies have been proposed in decades. The technical advancement and progress of understanding of cellular differentiation have contributed to the development of basis of cellular therapy. This attractive therapeutic option has been advanced from original embryonic stem cells to more effective cellular fractions such as Muse cells. Indeed several cellular therapies including bone marrow-derived stem cells or peripheral blood-derived stem cells were initiated; the recent most organized clinical trials could not demonstrate its efficacy. Thus, truly innovative cellular therapy is needed to meet the scientific demands, and Muse cell administration is the remaining approach to this. In this article, we will discuss the current development and status of cellular therapy toward chronic liver failure.
肝脏疾病是全球医疗保健中导致死亡的主要原因之一。此外，慢性肝功能衰竭，如肝硬化，是导致这些致命情况的罪魁祸首。然而，对于这种终末期疾病，只有肝移植是一种既定的治疗方法，尽管这种挽救治疗方法的可及性相当有限。因此，人工肝脏设备或细胞给药等新疗法被认为是可行的。特别是细胞疗法在几十年前就已经提出。细胞分化的技术进步和理解的进展为细胞疗法的基础发展做出了贡献。这种有吸引力的治疗选择已经从最初的胚胎干细胞发展到更有效的细胞成分，如 Muse 细胞。事实上，已经启动了包括骨髓源性干细胞或外周血源性干细胞在内的几种细胞疗法，但最近组织最严密的临床试验未能证明其疗效。因此，需要真正创新的细胞疗法来满足科学需求，而 Muse 细胞给药是满足这一需求的剩余方法。本文将讨论细胞疗法治疗慢性肝功能衰竭的现状和进展。
